


**HERSHEY CENTER FOR
APPLIED RESEARCH**
Here for tomorrow.



Tenant Showcase

Apogee Biotechnology Corporation

Hershey Center for Applied Research's first private company tenant, Apogee Biotechnology Corporation, established its headquarters on the HCAR campus in February of 2008. Apogee, a spinoff of the Penn State College of Medicine's Department of Pharmacology, is dedicated to developing its program for the treatment of solid tumors and a variety of chronic inflammatory diseases, as well as in indications of damaging acute inflammation. Research is focused on small molecule inhibitors of sphingosine kinase, an enzyme known to drive cell proliferation and inflammation. Sphingosine kinase is overactive in several diseases such as cancer, diabetic retinopathy, inflammatory bowel disease, arthritis and atherosclerosis.

Apogee's lead compound is the first-in-class non-lipid inhibitor of sphingosine kinase. It has shown promising biological activity in several disease models. Apogee is poised to begin Phase I clinical trials of ABC294640 following Food and Drug Administration (FDA) approval of its Investigational New Drug (IND) application.

Apeliotus Vision Science

Leasing of HCAR's Building One Technology Suites was completed with the addition of Apeliotus Vision Science, a company developing a diagnostic device for the detection of age-related macular degeneration (AMD).

Apeliotus Vision Science is a recent spinout of Apeliotus Technologies, a Georgia-based company that develops and commercializes medical devices based on university inventions. In the U.S. alone, an alarming one in six people over age 65 have AMD, a figure that reaches one in three for people over age 75. AMD is the leading cause of adult vision loss and blindness in developed countries. While there is a growing array of treatment options, there is currently no practical, low-cost method for detecting AMD at the early stages of the disease. Apeliotus Vision Science's objective is to provide a simple, cost-effective tool for early diagnosis of AMD, before patients have suffered significant visual impairment.

Better Bowls

Based at HCAR, Better Bowls produces great-tasting food products that use healthier formulations, natural ingredients and convenient packaging to help consumers stay healthy.

Dr. Malathy Nair, one of the three partners behind the startup, set out to create low

sodium, low fat foods after her mother suffered a major heart attack and needed a healthier substitute to the puddings and gelatins available in hospitals and retail stores.

Today, the products help prevent and manage health issues including obesity, diabetes and high blood pressure with healthy amounts of fiber, protein and calcium in each serving. The brand's chocolate and vanilla instant puddings and strawberry and orange gelatins are available in single serve cups and family-sized pouches.

ClawNor

ClawNor, an early-stage company focused on producing reagents for diagnosis and therapy of human papillomavirus (HPV) infection, was incorporated in 1996 and until recently, was focused on consulting services.

The company will soon begin production of established monoclonal antibodies for type specific recognition of HPV. A number of R43 applications are pending that focus on development of aptamers for recognition of HPV-infected cells and type-specific recognition of HPV types, with the ultimate goal of replacing the monoclonal antibodies with more affordable and widely available aptamers. ClawNor presently holds one U.S. patent for a topical therapeutic reagent which shows promising efficacy for the eradication of HPV infections. The company expects to employ 4-5 researchers within the next year.

IDE Group

The IDE Group Inc. of Australia is the first international company to open an office at HCAR. The 6-year-old company, based in Sydney, specializes in the design of medical devices, complex manufacturing processes and prototype fabrication for early stage companies.

Richard Sokolov, one of the founders, learned about HCAR when Jack Atchason, Director of Business Development, attended a conference in Australia. The state Department of Community and Economic Development supported the international outreach.

Keystone Nano

Keystone Nano is a development-stage company working at the interface between nanotechnology and the life sciences. Its researchers create nanoparticles that protect and selectively deliver active compounds such as chemotherapeutics or small interfering RNA to tumors. The company has licensed technology from Penn State University and is developing proprietary nanoparticle technology.

The company's venture began in the Zetachron Technology Incubator in State College, Pennsylvania and recently expanded with the addition of its second laboratory and office at HCAR. Keystone Nano is led by CEO Jeff Davidson, MBA; Chief Science Officer James Adair, PhD.; Chief Medical Officer Mark Kester, PhD; and Research Manager Mylisa Parette, Ph.D. Together with its research staff, the team is successfully transferring technology from academia to business and beyond.

Penn State College of Medicine Department of Pharmacology

The Department of Pharmacology at Penn State College of Medicine has interests in both basic and clinical areas of research, although its emphasis is on the basic sciences. The Department is constantly adding to its technical expertise by attracting new or affiliated members to its growing staff.

Penn State College of Medicine Office of Technology Development

The Office of Technology Development serves the College of Medicine and Milton S. Hershey Medical Center, and the scientific and business communities by:

- facilitating translation of creative work into new products and processes
- enabling constructive, responsible exchange of materials and ideas with outside partners
- assisting with access to COM and HMC expertise

The Office of Technology Development works closely with other research mission offices, including Research Affairs, Research Development and Clinical Trials, and with Penn State Tech Transfer including the Intellectual Property, Industrial Research and Research Commercialization offices.

Penn State Hershey Sleep and Research Treatment Center

With collaboration between Penn State Milton S. Hershey Medical Center and Penn State College of Medicine departments of Psychiatry and Medicine, the 12-bed Sleep Center helps children and adults who are affected by nighttime problems such as insomnia, sleep apnea, narcolepsy, hypersomnia, night terrors, sleep walking and bed wetting. In routine sleep studies, various body systems are monitored while patients sleep. The Sleep Center makes recommendations to the patients' physicians for specific treatment.

In addition to its contributions to scientific research aimed to better understand the mechanisms of sleep disorders, this center also serves as an educational resource for those in the medical profession and community at large.